-
Signature
-
/s/ Matthew Kowalsky, Attorney-in-Fact
-
Stock symbol
-
SGTX
-
Transactions as of
-
Aug 11, 2023
-
Transactions value $
-
-$7,952
-
Form type
-
4
-
Date filed
-
8/11/2023, 04:10 PM
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
transaction |
SGTX |
Stock Option (Right to Buy) |
Disposed to Issuer |
-$4.54K |
-683 |
-100% |
$6.64* |
0 |
Aug 11, 2023 |
Common Stock |
683 |
$8.28 |
Direct |
F1, F2 |
transaction |
SGTX |
Stock Option (Right to Buy) |
Disposed to Issuer |
-$3.41K |
-683 |
-100% |
$5.00* |
0 |
Aug 11, 2023 |
Common Stock |
683 |
$9.92 |
Direct |
F1, F2 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
Remarks:
Capitalized terms used herein without definition have the meanings ascribed to them in the Agreement and Plan of Merger, dated as of June 28, 2023, among Sigilon Therapeutics, Inc., Eli Lilly and Company and Shenandoah Acquisition Corporation. (the "Merger Agreement").